Loading…

Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B

The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra PCR assay (Abacus Diagnostic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology 2020-03, Vol.58 (4)
Main Authors: Savolainen, Roosa, Koskinen, Juha M, Mentula, Silja, Koskinen, Janne O, Kaukoranta, Suvi-Sirkku
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693
cites cdi_FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693
container_end_page
container_issue 4
container_start_page
container_title Journal of clinical microbiology
container_volume 58
creator Savolainen, Roosa
Koskinen, Juha M
Mentula, Silja
Koskinen, Janne O
Kaukoranta, Suvi-Sirkku
description The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomEra PCR. Of these specimens, 157 were also tested with the TechLab MEIA. The sensitivity of the mariPOC test for GDH was slightly lower (95.2%) than that obtained with the TechLab assay (100.0%), but no toxin-positive cases were missed. The sensitivity of the mariPOC test for the detection of toxigenic by analyzing toxin expression was better (81.6%) than that of the TechLab assay (71.1%). The analytical specificities for the mariPOC and the TechLab tests were 98.3% and 100.0% for GDH and 100.0% and 99.2% for toxin A/B, respectively. The analytical specificity of the GenomEra method was 100.0%. The mariPOC and TechLab GDH tests and GenomEra PCR had high negative predictive values of 99.3%, 98.3%, and 99.7%, respectively, in excluding infection with toxigenic The mariPOC toxin A/B test and GenomEra PCR had an identical analytical positive predictive value of 100%, providing highly reliable information about toxin expression and the presence of toxin genes, respectively.
doi_str_mv 10.1128/JCM.01872-19
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7098770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31941691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693</originalsourceid><addsrcrecordid>eNpVkUFP20AQhVeoFaRpbz2j_QF1smN7vfYFCUyatgKFQyr1thq8s2SR4428m4iIP1-noQhOc5hv3tO8x9hXEBOAtJz-qm8nAkqVJlCdsBGIqkyKQvz5wEZCVDIByNQZ-xTCoxCQ51KesrMMqhyKCkbs-a73YUNNdDvisx22W4zOd9xbHlfE19i7u0XNlxQit77n1xQP8JGoWx9i74zzzlDgxlnrGtcSn7fbiGuMNPCrven9A3UYiGNn-NI_uS7wy-nVZ_bRYhvoy8scs9_fZ8v6R3KzmP-sL2-SJivzmJCyooECURlKS9tIq1KFlFsJlMu8MJlFiZaKykjM0sKaPJMkSwMVyqaosjG7OOputvdrMg11scdWb3o3vLfXHp1-v-ncSj_4nVZDlkqJQeDbUaAZwgo92ddbEPpQgh5K0P9K0HDwO3_r9wr_Tz37C-bMhhE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>Savolainen, Roosa ; Koskinen, Juha M ; Mentula, Silja ; Koskinen, Janne O ; Kaukoranta, Suvi-Sirkku</creator><contributor>Onderdonk, Andrew B.</contributor><creatorcontrib>Savolainen, Roosa ; Koskinen, Juha M ; Mentula, Silja ; Koskinen, Janne O ; Kaukoranta, Suvi-Sirkku ; Onderdonk, Andrew B.</creatorcontrib><description>The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomEra PCR. Of these specimens, 157 were also tested with the TechLab MEIA. The sensitivity of the mariPOC test for GDH was slightly lower (95.2%) than that obtained with the TechLab assay (100.0%), but no toxin-positive cases were missed. The sensitivity of the mariPOC test for the detection of toxigenic by analyzing toxin expression was better (81.6%) than that of the TechLab assay (71.1%). The analytical specificities for the mariPOC and the TechLab tests were 98.3% and 100.0% for GDH and 100.0% and 99.2% for toxin A/B, respectively. The analytical specificity of the GenomEra method was 100.0%. The mariPOC and TechLab GDH tests and GenomEra PCR had high negative predictive values of 99.3%, 98.3%, and 99.7%, respectively, in excluding infection with toxigenic The mariPOC toxin A/B test and GenomEra PCR had an identical analytical positive predictive value of 100%, providing highly reliable information about toxin expression and the presence of toxin genes, respectively.</description><identifier>ISSN: 0095-1137</identifier><identifier>EISSN: 1098-660X</identifier><identifier>DOI: 10.1128/JCM.01872-19</identifier><identifier>PMID: 31941691</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Immunoassays</subject><ispartof>Journal of clinical microbiology, 2020-03, Vol.58 (4)</ispartof><rights>Copyright © 2020 American Society for Microbiology.</rights><rights>Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693</citedby><cites>FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693</cites><orcidid>0000-0002-0746-7389</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098770/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098770/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3188,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31941691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Onderdonk, Andrew B.</contributor><creatorcontrib>Savolainen, Roosa</creatorcontrib><creatorcontrib>Koskinen, Juha M</creatorcontrib><creatorcontrib>Mentula, Silja</creatorcontrib><creatorcontrib>Koskinen, Janne O</creatorcontrib><creatorcontrib>Kaukoranta, Suvi-Sirkku</creatorcontrib><title>Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B</title><title>Journal of clinical microbiology</title><addtitle>J Clin Microbiol</addtitle><description>The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomEra PCR. Of these specimens, 157 were also tested with the TechLab MEIA. The sensitivity of the mariPOC test for GDH was slightly lower (95.2%) than that obtained with the TechLab assay (100.0%), but no toxin-positive cases were missed. The sensitivity of the mariPOC test for the detection of toxigenic by analyzing toxin expression was better (81.6%) than that of the TechLab assay (71.1%). The analytical specificities for the mariPOC and the TechLab tests were 98.3% and 100.0% for GDH and 100.0% and 99.2% for toxin A/B, respectively. The analytical specificity of the GenomEra method was 100.0%. The mariPOC and TechLab GDH tests and GenomEra PCR had high negative predictive values of 99.3%, 98.3%, and 99.7%, respectively, in excluding infection with toxigenic The mariPOC toxin A/B test and GenomEra PCR had an identical analytical positive predictive value of 100%, providing highly reliable information about toxin expression and the presence of toxin genes, respectively.</description><subject>Immunoassays</subject><issn>0095-1137</issn><issn>1098-660X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkUFP20AQhVeoFaRpbz2j_QF1smN7vfYFCUyatgKFQyr1thq8s2SR4428m4iIP1-noQhOc5hv3tO8x9hXEBOAtJz-qm8nAkqVJlCdsBGIqkyKQvz5wEZCVDIByNQZ-xTCoxCQ51KesrMMqhyKCkbs-a73YUNNdDvisx22W4zOd9xbHlfE19i7u0XNlxQit77n1xQP8JGoWx9i74zzzlDgxlnrGtcSn7fbiGuMNPCrven9A3UYiGNn-NI_uS7wy-nVZ_bRYhvoy8scs9_fZ8v6R3KzmP-sL2-SJivzmJCyooECURlKS9tIq1KFlFsJlMu8MJlFiZaKykjM0sKaPJMkSwMVyqaosjG7OOputvdrMg11scdWb3o3vLfXHp1-v-ncSj_4nVZDlkqJQeDbUaAZwgo92ddbEPpQgh5K0P9K0HDwO3_r9wr_Tz37C-bMhhE</recordid><startdate>20200325</startdate><enddate>20200325</enddate><creator>Savolainen, Roosa</creator><creator>Koskinen, Juha M</creator><creator>Mentula, Silja</creator><creator>Koskinen, Janne O</creator><creator>Kaukoranta, Suvi-Sirkku</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0746-7389</orcidid></search><sort><creationdate>20200325</creationdate><title>Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B</title><author>Savolainen, Roosa ; Koskinen, Juha M ; Mentula, Silja ; Koskinen, Janne O ; Kaukoranta, Suvi-Sirkku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Immunoassays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Savolainen, Roosa</creatorcontrib><creatorcontrib>Koskinen, Juha M</creatorcontrib><creatorcontrib>Mentula, Silja</creatorcontrib><creatorcontrib>Koskinen, Janne O</creatorcontrib><creatorcontrib>Kaukoranta, Suvi-Sirkku</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Savolainen, Roosa</au><au>Koskinen, Juha M</au><au>Mentula, Silja</au><au>Koskinen, Janne O</au><au>Kaukoranta, Suvi-Sirkku</au><au>Onderdonk, Andrew B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B</atitle><jtitle>Journal of clinical microbiology</jtitle><addtitle>J Clin Microbiol</addtitle><date>2020-03-25</date><risdate>2020</risdate><volume>58</volume><issue>4</issue><issn>0095-1137</issn><eissn>1098-660X</eissn><abstract>The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomEra PCR. Of these specimens, 157 were also tested with the TechLab MEIA. The sensitivity of the mariPOC test for GDH was slightly lower (95.2%) than that obtained with the TechLab assay (100.0%), but no toxin-positive cases were missed. The sensitivity of the mariPOC test for the detection of toxigenic by analyzing toxin expression was better (81.6%) than that of the TechLab assay (71.1%). The analytical specificities for the mariPOC and the TechLab tests were 98.3% and 100.0% for GDH and 100.0% and 99.2% for toxin A/B, respectively. The analytical specificity of the GenomEra method was 100.0%. The mariPOC and TechLab GDH tests and GenomEra PCR had high negative predictive values of 99.3%, 98.3%, and 99.7%, respectively, in excluding infection with toxigenic The mariPOC toxin A/B test and GenomEra PCR had an identical analytical positive predictive value of 100%, providing highly reliable information about toxin expression and the presence of toxin genes, respectively.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>31941691</pmid><doi>10.1128/JCM.01872-19</doi><orcidid>https://orcid.org/0000-0002-0746-7389</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0095-1137
ispartof Journal of clinical microbiology, 2020-03, Vol.58 (4)
issn 0095-1137
1098-660X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7098770
source American Society for Microbiology Journals; PubMed Central
subjects Immunoassays
title Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A20%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20Evaluation%20of%20the%20mariPOC%20Test%20for%20Detection%20of%20Clostridioides%20difficile%20Glutamate%20Dehydrogenase%20and%20Toxins%20A/B&rft.jtitle=Journal%20of%20clinical%20microbiology&rft.au=Savolainen,%20Roosa&rft.date=2020-03-25&rft.volume=58&rft.issue=4&rft.issn=0095-1137&rft.eissn=1098-660X&rft_id=info:doi/10.1128/JCM.01872-19&rft_dat=%3Cpubmed_cross%3E31941691%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-e7f0c16aa7de28fc5f727ae4f51e4546d3fa5afe69d5a326fd435e58d19a5c693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31941691&rfr_iscdi=true